OPTOMICS - Combining optoacoustic imaging phenotypes and multi-omics to advance diabetes healthcare (Validation Study)

Study identification

• EU PAS number:
  EUPAS1000000392
• Study ID:
  1000000392
• Official title and acronym:
  OPTOMICS - Combining optoacoustic imaging phenotypes and multi-omics to advance diabetes healthcare (Validation Study)
• DARWIN EU® study:
  No
• Study countries:
  Estonia
• Study description:
  Diabetes has emerged as a global pandemic affecting more than 420 million people worldwide, a number expected to further rise in the next decades. ; The disease has very heterogeneous outcomes and accurate patient staging or prediction of subsets of individuals likely to develop disease and/or progress to disease complications are currently unmet clinical challenges in need of urgent attention. ; OPTOMICS aims to research methodology that can deliver a paradigm shift in type 2 diabetes healthcare, by integrating:; - molecular phenotyping,; - a new generation of phenotypic measurements in humans, representative of diabetes onset and progression, allowed by novel portable and non-invasive optoacoustic technology, and; - cutting-edge computational approaches leveraging progress in Artificial Intelligence.; This research will develop and validate a digital twin model that catalyses a step change in shortening the path to translation, enabling applications in the entire spectrum from target identification & prevention/prognosis to patient stratification for type 2 diabetes and its complications. ; In addition to the research and technology goals, OPTOMICS places special attention to the ethical needs and implications of the work performed and further aims at exemplary project management, human measurements, dissemination and communication activities and updating an adept exploitation plan for the digital twin developed.
• Study status:
  Ongoing

Research institutions and networks

Institutions

University of Tartu

Estonia

Study timelines

Date when funding contract was signed

Actual: 01/01/2021

Study start date

Actual: 09/10/2023

Date of final study report

Planned: 31/12/2026

Sources of funding

EU institutional research programme

More details on funding

Horizon 2020 Programme, Grant Agreement no 101017802.

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable